TWI615406B - 特異性結合ｅｒｂｂ３之抗體及其用途 - Google Patents

特異性結合ｅｒｂｂ３之抗體及其用途 Download PDF

Info

Publication number: TWI615406B
Authority: TW; Taiwan
Prior art keywords: antibody; cancer; erbb3; antigen; binding fragment
Prior art date: 2015-12-07

Application number

TW105140259A

Other languages

English (en)

Chinese (zh)

Other versions

TW201726742A (zh

Inventor

裵銅球

金美英

許英美

洪美琳

Original Assignee

梨樹愛博思股份有限公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-07

Filing date

2016-12-06

Publication date

2018-02-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59013461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI615406(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-12-06 Application filed by 梨樹愛博思股份有限公司 filed Critical 梨樹愛博思股份有限公司

2017-08-01 Publication of TW201726742A publication Critical patent/TW201726742A/zh

2018-02-21 Application granted granted Critical

2018-02-21 Publication of TWI615406B publication Critical patent/TWI615406B/zh

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

TW105140259A 2015-12-07 2016-12-06 特異性結合ｅｒｂｂ３之抗體及其用途 TWI615406B (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
??10-2015-0173281		2015-12-07
KR1020150173281A KR101746152B1 (ko)	2015-12-07	2015-12-07	ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도

Publications (2)

Publication Number	Publication Date
TW201726742A TW201726742A (zh)	2017-08-01
TWI615406B true TWI615406B (zh)	2018-02-21

Family

ID=59013461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW105140259A TWI615406B (zh)	2015-12-07	2016-12-06	特異性結合ｅｒｂｂ３之抗體及其用途

Country Status (14)

Country	Link
US (1)	US10413607B2 (pl)
EP (2)	EP3778647B1 (pl)
JP (2)	JP6982574B2 (pl)
KR (1)	KR101746152B1 (pl)
CN (2)	CN112472804B (pl)
AR (1)	AR107012A1 (pl)
AU (1)	AU2016365506B2 (pl)
CA (1)	CA3000835C (pl)
ES (1)	ES2891990T3 (pl)
MX (1)	MX394911B (pl)
PL (1)	PL3362480T3 (pl)
RU (1)	RU2707121C9 (pl)
TW (1)	TWI615406B (pl)
WO (1)	WO2017099362A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220275081A1 (en) *	2018-10-17	2022-09-01	Good T Cells, Inc.	Binding molecule specific for lrig-1 protein and use thereof
US12551584B1 (en)	2020-12-07	2026-02-17	Actinium Pharmaceuticals, Inc.	Lewis Y radioimmunotherapy for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201329103A (zh) *	2011-09-30	2013-07-16	Regeneron Pharma	抗－ＥｒｂＢ３抗體及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0173281B1 (ko)	1996-11-30	1999-02-18	양재신	자동차의 램프 각도 조절장치
SG178789A1 (en) *	2007-02-16	2012-03-29	Merrimack Pharmaceuticals Inc	Antibodies against erbb3 and uses thereof
BRPI0911652A2 (pt) *	2008-04-11	2015-08-04	Merrimack Pharmaceuticals Inc	Ligantes de albumina sérica humana e seus conjugados
CN102282168A (zh)	2008-11-18	2011-12-14	梅里麦克制药股份有限公司	人血清白蛋白接头以及其结合物
KR101798679B1 (ko)	2010-03-11	2017-11-16	메리맥 파마슈티컬즈, 인크.	３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도
US8481687B2 (en) *	2010-04-09	2013-07-09	Aveo Pharmaceuticals, Inc.	Anti-ErbB3 antibodies
SG187908A1 (en) *	2010-08-20	2013-03-28	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
KR20140033152A (ko) *	2011-06-20	2014-03-17	교와 핫꼬 기린 가부시키가이샤	항erbB3 항체
US9273143B2 (en)	2011-09-30	2016-03-01	Regeneron Pharmaceuticals, Inc.	Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
WO2015048008A2 (en)	2013-09-24	2015-04-02	Medimmune, Llc	Binding molecules specific for her3 and uses thereof

2015
- 2015-12-07 KR KR1020150173281A patent/KR101746152B1/ko active Active
2016
- 2016-11-02 CN CN202011145330.1A patent/CN112472804B/zh active Active
- 2016-11-02 US US15/563,227 patent/US10413607B2/en active Active
- 2016-11-02 RU RU2018113269A patent/RU2707121C9/ru active
- 2016-11-02 CN CN201680021403.1A patent/CN107683292B/zh active Active
- 2016-11-02 AU AU2016365506A patent/AU2016365506B2/en active Active
- 2016-11-02 CA CA3000835A patent/CA3000835C/en active Active
- 2016-11-02 PL PL16873228T patent/PL3362480T3/pl unknown
- 2016-11-02 EP EP20196712.2A patent/EP3778647B1/en active Active
- 2016-11-02 ES ES16873228T patent/ES2891990T3/es active Active
- 2016-11-02 JP JP2018542089A patent/JP6982574B2/ja active Active
- 2016-11-02 MX MX2018004228A patent/MX394911B/es unknown
- 2016-11-02 EP EP16873228.7A patent/EP3362480B1/en active Active
- 2016-11-02 WO PCT/KR2016/012545 patent/WO2017099362A1/en not_active Ceased
- 2016-12-06 TW TW105140259A patent/TWI615406B/zh active
- 2016-12-07 AR ARP160103758A patent/AR107012A1/es unknown
2020
- 2020-03-19 JP JP2020049129A patent/JP6989645B2/ja active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201329103A (zh) *	2011-09-30	2013-07-16	Regeneron Pharma	抗－ＥｒｂＢ３抗體及其用途

Also Published As

Publication number	Publication date
WO2017099362A1 (en)	2017-06-15
US10413607B2 (en)	2019-09-17
CN112472804A (zh)	2021-03-12
RU2018113269A (ru)	2019-10-18
BR112018006900A2 (pt)	2018-10-16
US20180085455A1 (en)	2018-03-29
JP6982574B2 (ja)	2021-12-17
JP6989645B2 (ja)	2022-01-05
EP3778647A1 (en)	2021-02-17
EP3362480A4 (en)	2019-06-05
MX394911B (es)	2025-03-24
CA3000835C (en)	2020-06-09
MX2018004228A (es)	2018-05-15
ES2891990T3 (es)	2022-02-01
AU2016365506B2 (en)	2019-06-20
EP3362480A1 (en)	2018-08-22
AR107012A1 (es)	2018-03-14
KR101746152B1 (ko)	2017-06-13
AU2016365506A1 (en)	2018-04-12
TW201726742A (zh)	2017-08-01
CN112472804B (zh)	2024-07-23
JP2020117512A (ja)	2020-08-06
RU2707121C2 (ru)	2019-11-22
PL3362480T3 (pl)	2022-01-03
CN107683292A (zh)	2018-02-09
EP3778647B1 (en)	2026-02-25
JP2018536026A (ja)	2018-12-06
CN107683292B (zh)	2021-06-08
RU2707121C9 (ru)	2020-06-16
AU2016365506A9 (en)	2018-11-01
CA3000835A1 (en)	2017-06-15
EP3362480B1 (en)	2021-08-04
RU2018113269A3 (pl)	2019-10-18

Publication	Publication Date	Title
JP6967853B2 (ja)	2021-11-17	ＥｒｂＢ−２およびＥｒｂＢ−３に結合する抗体
US10934350B2 (en)	2021-03-02	Humanized or affinity-matured anti ang-2 antibody and uses thereof
RU2402569C2 (ru)	2010-10-27	Человеческие антитела к рецептору эпидермального фактора роста
Ko et al.	2015	Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer
US20230398229A1 (en)	2023-12-14	Antibody drug conjugates comprising sting agonists, combinations and methods of use
US12053530B2 (en)	2024-08-06	Plectin-1 binding antibodies and uses thereof
JP6989645B2 (ja)	2022-01-05	ＥｒｂＢ３に特異的に結合する抗体、及びその用途
JP7304815B2 (ja)	2023-07-07	Ｅｒｂｂ－２、ｅｒｂｂ－２／ｅｒｂｂ－３陽性腫瘍を有する個体の処置のための、ｅｒｂ－２及びｅｒｂｂ－３の細胞外部分上のエピトープに結合する抗原結合部位を含むｅｒｂｂ－２標的化剤及び二重特異性抗体
JP2021500320A (ja)	2021-01-07	癌の治療のための配合剤
CN119587691A (zh)	2025-03-11	抗her2抗体药物偶联物联合抗her2抗体治疗肿瘤
KR101927732B1 (ko)	2018-12-11	ＥｒｂＢ3에 특이적으로 결합하는 항체를 포함하는 항암제 내성 암의 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
BR112018006900B1 (pt)	2024-08-06	Anticorpo ou um seu fragmento antígeno-ligante que se liga especificamente a erbb3, e composição farmacêutica para o tratamento de uma doença relacionada à ativação ou superexpressão da proteína erbb3
WO2022144025A1 (zh)	2022-07-07	一种抗erbb3受体的抗体或其抗原结合片段及其医药用途